Emerging strategies to target cancer metabolism and improve radiation therapy outcomes

Br J Radiol. 2020 Nov 1;93(1115):20200067. doi: 10.1259/bjr.20200067. Epub 2020 Jun 23.

Abstract

Cancer-specific metabolic changes support the anabolic needs of the rapidly growing tumor, maintain a favorable redox balance, and help cells adapt to microenvironmental stresses like hypoxia and nutrient deprivation. Radiation is extensively applied in a large number of cancer treatment protocols but despite its curative potential, radiation resistance and treatment failures pose a serious problem. Metabolic control of DNA integrity and genomic stability can occur through multiple processes, encompassing cell cycle regulation, nucleotide synthesis, epigenetic regulation of gene activity, and antioxidant defenses. Given the important role of metabolic pathways in oxidative damage responses, it is necessary to assess the potential for tumor-specific radiosensitization by novel metabolism-targeted therapies. Additionally, there are opportunities to identify molecular and functional biomarkers of vulnerabilities to combination treatments, which could then inform clinical decisions. Here, we present a curated list of metabolic pathways in the context of ionizing radiation responses. Glutamine metabolism influences DNA damage responses by mechanisms such as synthesis of nucleotides for DNA repair or of glutathione for ROS detoxification. Repurposed oxygen consumption inhibitors have shown promising radiosensitizing activity against murine model tumors and are now in clinical trials. Production of 2-hydroxy glutarate by isocitrate dehydrogenase1/2 neomorphic oncogenic mutants interferes with the function of α-ketoglutarate-dependent enzymes and modulates Ataxia Telangiectasia Mutated (ATM) signaling and glutathione pools. Radiation-induced oxidative damage to membrane phospholipids promotes ferroptotic cell loss and cooperates with immunotherapies to improve tumor control. In summary, there are opportunities to enhance the efficacy of radiotherapy by exploiting cell-inherent vulnerabilities and dynamic microenvironmental components of the tumor.

Publication types

  • Review

MeSH terms

  • Adaptation, Physiological
  • Animals
  • Ataxia Telangiectasia Mutated Proteins / metabolism
  • DNA / physiology
  • DNA Damage / physiology
  • DNA Repair / physiology
  • Genomic Instability
  • Glutamine / metabolism
  • Glutarates / metabolism
  • Glutathione / metabolism
  • Humans
  • Immunotherapy
  • Isocitrate Dehydrogenase / genetics
  • Ketoglutaric Acids / metabolism
  • Lipid Peroxidation
  • Mice
  • Neoplasms / metabolism*
  • Neoplasms / radiotherapy*
  • Neoplasms / therapy
  • Nucleotides / biosynthesis
  • Oxygen Consumption / drug effects
  • Phospholipids / radiation effects
  • Radiation Tolerance / physiology*
  • Radiation-Sensitizing Agents / pharmacology
  • Reactive Oxygen Species / metabolism
  • Stress, Physiological
  • Treatment Outcome
  • Tumor Microenvironment / physiology

Substances

  • Glutarates
  • Ketoglutaric Acids
  • Nucleotides
  • Phospholipids
  • Radiation-Sensitizing Agents
  • Reactive Oxygen Species
  • Glutamine
  • alpha-hydroxyglutarate
  • DNA
  • IDH2 protein, human
  • Isocitrate Dehydrogenase
  • ATM protein, human
  • Ataxia Telangiectasia Mutated Proteins
  • Glutathione